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Hypertension affects approximately 70% of patients with dia-
betes and is approximately twice as common in persons with 
diabetes as in those without. At the age of 45, around 40% of 
patients with type 2 diabetes are hypertensive, increasing to 
60% by the age of 75 [1]. The overlap between hypertension 
and diabetes substantially increases the risk of ischemic cere-
brovascular disease, retinopathy, and sexual dysfunction. Ef-
fective control of blood pressure (BP) has been associated with 
a reduction in both the microvascular and macrovascular com-
plications of diabetes. Thus, a major challenge for people with 
diabetes is the management of hypertension. However, reach-
ing a target level (less than 130/80 mm Hg) of BP control has 
been difficult to achieve. Studies suggest that many diabetic 
patients do not achieve target BP control. For example, in the 
Third National Health and Nutrition Examination Survey 
(NHANES-III), 31% of all diabetic patients and nearly 60% of 
those with previously diagnosed hypertension had a BP 
>140/90 mm Hg [2,3]. Among elderly diabetic patients seen 
in an academic medical center, 85% had a BP ≥130/85 mm Hg 
[4,5]. Berlowitz et al. [6,7] reported that diabetic patients with 
hypertension received less intensive antihypertensive therapy 
than patients without diabetes. Using a threshold for hyper-
tension control of ≤140/90 mm Hg, they found that 73% of 
diabetic hypertensive subjects did not reach this target BP.
  Little is known about the prevalence and control of hyper-
tension among patients with diabetes in Korea. Lim et al. [2] 
reported that the age-adjusted prevalence of hypertension in 
the Korean population was 60.4%. However, that study did not 
include a recent study of prevalence, awareness and control of 
hypertension among diabetic Koreans. The Hypertension Op-
timal Treatment (HOT) study and the UK Prospective Diabe-
tes Studies (UKPDS) have shown the benefits of achieving 
tighter BP control [1,8]. In the HOT study, diabetic patients 
randomized to a target diastolic BP of 80 mm Hg or less had a 
50% reduction in major cardiovascular events compared with 
those with a target diastolic BP of 90 or less [8]. Moreover, the 
benefits of tight BP control in patients with diabetes exceed 
the benefits of tight glycemic control and extend not only to 
the prevention of macrovascular disease, but also to the pre-
vention of microvascular complications [1]. However, in the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
BP study, investigators evaluated the potential benefits of tar-
geting a systolic BP level below 120 mm Hg versus a level be-
low 140 mm Hg in patients with type 2 diabetes (34% of 
whom had cardiovascular disease) [9]. After 4.7 years, there 
were no significant between-group differences in the annual 
rate of the primary outcome, a composite of nonfatal myocar-
dial infarction, nonfatal stroke, or death from cardiovascular 
causes. Serious adverse events that were attributed to BP med-
ication were more frequent in the intensive-therapy group. As 
a result of the factorial design of the overall ACCORD study 
and the inclusion and exclusion criteria that were applied, the 
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study’s statistical power was reduced, and the event rate was 
lower than expected. Thus, the design and results of the AC-
CORD BP study leave unresolved the issue of the optimal BP 
target in patients with diabetes. Therefore, lowering systolic 
BP from the 135mm Hg to around 120 mm Hg does not reduce 
most cardiovascular events or the rate of death, and most of 
the benefit from lowering BP is achieved by targeting a goal of 
less than 140 mm Hg. Compliance is an important factor re-
lated to optimal BP control. Shea et al. [10] reported that non-
compliance with an antihypertensive regimen was strongly as-
sociated with severe and uncontrolled hypertension. Also, in 
this issue, Seo et al.’s [11] study finds a difference between anti-
hypertensive medication compliance and BP control. It is im-
portant to realize that there is still much to be learned about 
the doctor-patient relationship and its effects on hypertension 
treatment [10]. Affecting the renin–angiotensin–aldosterone 
system appears particularly useful in diabetic people, certainly 
for the prevention of poor renal outcomes [12-14]. Calcium 
channel blockers are recommended in a recent study that sug-
gests favorable outcomes with preservation of the glomerular 
filtration rate [15]. Thiazide plus cardiospecific beta-blocker 
combinations are probably undesirable compared with angio-
tensin-converting enzyme inhibitors plus calcium channel 
blockers, but combination alpha/beta-blockers may have par-
ticularly desirable characteristics and, in many comparisons, 
BP levels have not been equal on different regimens. Therefore 
it becomes uncertain whether different medications or differ-
ent BP goals are what is being compared [16]. Wong et al.’s [17] 
study also showed that 80% to 83% of diabetic patients with 
hypertension received drug therapy, but only 12% to 35% of 
patients controlled their BP below 130/80 mm Hg, depending 
on various data sources. 
  In this issue, Seo et al.’s [11] study results are similar to the 
findings of other studies. They reported that 57.5% of all pa-
tients were over the age of sixty. Their mean HbA1c was 7.6± 
1.5%. Among antihypertensive medication users, 39.9% had a 
BP of <130 mm Hg and <80 mm Hg and 60.1% had a BP ≥130 
mm Hg or ≥ 80 mm Hg. The answer “BP is generally felt to be 
under good control” was given by 75.1% of antihypertensive 
medication users, and of these patients, 26.4% had a BP of 
<130 mm Hg and <80 mm Hg and 73.6% had a BP ≥130 mm 
Hg or ≥80 mm Hg. A total of 75.5% of antihypertensive medi-
cation users answered that they had taken antihypertensive 
medication every day for the most recent 2 weeks. “Forgetful-
ness” was the most frequent reason given for noncompliance 
for those who did not regularly take antihypertensive medica-
tion. Seo et al.’s [11] study is the first epidemiologic study of 
prevalence, awareness and control of hypertension among dia-
betic Koreans. However this study had several limitations. It 
used survey-based data (interviews and medical records review) 
and a limited survey questionnaire, and therefore no causal re-
lationships could be precisely delineated. Also, information on 
duration of diabetes and exact age for diabetic patients was not 
included this study. In addition, they used subjects from 43 
university hospitals in Korea. Therefore, these results cannot 
be extrapolated to subjects in the general population.
  According to Seo et al.’s [11] study, tighter BP control is need-
ed to reduce complications of diabetes in Koreans. Also, we 
must balance the adverse effects of lowering BP with the bene-
fits of such treatment. Most importantly, we should be aware 
of the potential for the harmonious interaction of combined 
glucose and BP lowering. 
  We appreciate the devotion of study investigators, who are 
conducting important studies about prevalence, awareness and 
control of hypertension among diabetic Koreans and hope that 
expansion on these findings will yield even more useful results 
in the future.
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